Radiotherapy for localized sebaceous carcinoma of the eyelid: a retrospective analysis of 83 patients

Yoshiaki Takagawa, Wakana Tamaki, Shigenobu Suzuki, Koji Inaba, Naoya Murakami, Kana Takahashi, Hiroshi Igaki, Yuko Nakayama, Naoyuki Shigematsu, Jun Itami

Research output: Contribution to journalArticle

Abstract

The current study retrospectively analyzed the results of radiotherapy for clinically localized sebaceous carcinoma of the eyelid.We reviewed records of 83 patients with histologically confirmed sebaceous carcinoma who were treated radiotherapeutically between 1983 and 2015. Sixty-five patients (78%) were initially treated with radiotherapy of curative intent, while the remaining 18 patients underwent postoperative radiotherapy due to tumor recurrence or positive surgical margins. Thirty-seven patients belonged to T1-2, while 46 belonged to T3-4. All 83 patients were treated with radiotherapy with a median radiation dose of 60 Gy. The median follow-up period was 92.1 months (range, 2.8-310.3 months). At the time of analysis, 13 patients (15.1%) died, and 36 patients (43.3%) had local recurrence. The 7-year overall survival, freedom from neck lymph node recurrence, and local control (LC) rates for all patients were 83.5%, 75.5%, and 52.3%, respectively. Patients with a tumor size ≤10 mm had a higher 7-year LC rate than those with a tumor size >10 mm (58.8% vs 46.6%, P = 0.054). Neck lymph node recurrence was observed in 17 patients (20%) and significantly related to the tumor size. Late toxicity of an eyelid dysfunction of grade 3 was observed in 1 patient with T3 tumor. Radiotherapy for sebaceous carcinoma of the eyelid is a reasonable alternative to surgical resection for tumors <10 mm in size with few severe complications, while larger tumors should be treated with surgery if feasible.

Original languageEnglish
Pages (from-to)622-629
Number of pages8
JournalJournal of radiation research
Volume60
Issue number5
DOIs
Publication statusPublished - 2019 Oct 23

Fingerprint

Eyelids
radiation therapy
Radiotherapy
cancer
Carcinoma
tumors
Neoplasms
Recurrence
lymphatic system
Neck
Lymph Nodes
surgery
toxicity
margins
grade
Radiation
dosage
Survival

Keywords

  • eyelid
  • prognostic factor
  • radiotherapy
  • sebaceous carcinoma
  • toxicity

ASJC Scopus subject areas

  • Radiation
  • Radiology Nuclear Medicine and imaging
  • Health, Toxicology and Mutagenesis

Cite this

Takagawa, Y., Tamaki, W., Suzuki, S., Inaba, K., Murakami, N., Takahashi, K., ... Itami, J. (2019). Radiotherapy for localized sebaceous carcinoma of the eyelid: a retrospective analysis of 83 patients. Journal of radiation research, 60(5), 622-629. https://doi.org/10.1093/jrr/rrz046

Radiotherapy for localized sebaceous carcinoma of the eyelid : a retrospective analysis of 83 patients. / Takagawa, Yoshiaki; Tamaki, Wakana; Suzuki, Shigenobu; Inaba, Koji; Murakami, Naoya; Takahashi, Kana; Igaki, Hiroshi; Nakayama, Yuko; Shigematsu, Naoyuki; Itami, Jun.

In: Journal of radiation research, Vol. 60, No. 5, 23.10.2019, p. 622-629.

Research output: Contribution to journalArticle

Takagawa, Y, Tamaki, W, Suzuki, S, Inaba, K, Murakami, N, Takahashi, K, Igaki, H, Nakayama, Y, Shigematsu, N & Itami, J 2019, 'Radiotherapy for localized sebaceous carcinoma of the eyelid: a retrospective analysis of 83 patients', Journal of radiation research, vol. 60, no. 5, pp. 622-629. https://doi.org/10.1093/jrr/rrz046
Takagawa, Yoshiaki ; Tamaki, Wakana ; Suzuki, Shigenobu ; Inaba, Koji ; Murakami, Naoya ; Takahashi, Kana ; Igaki, Hiroshi ; Nakayama, Yuko ; Shigematsu, Naoyuki ; Itami, Jun. / Radiotherapy for localized sebaceous carcinoma of the eyelid : a retrospective analysis of 83 patients. In: Journal of radiation research. 2019 ; Vol. 60, No. 5. pp. 622-629.
@article{7f18875e67d2405a88f66c1dd1a80282,
title = "Radiotherapy for localized sebaceous carcinoma of the eyelid: a retrospective analysis of 83 patients",
abstract = "The current study retrospectively analyzed the results of radiotherapy for clinically localized sebaceous carcinoma of the eyelid.We reviewed records of 83 patients with histologically confirmed sebaceous carcinoma who were treated radiotherapeutically between 1983 and 2015. Sixty-five patients (78{\%}) were initially treated with radiotherapy of curative intent, while the remaining 18 patients underwent postoperative radiotherapy due to tumor recurrence or positive surgical margins. Thirty-seven patients belonged to T1-2, while 46 belonged to T3-4. All 83 patients were treated with radiotherapy with a median radiation dose of 60 Gy. The median follow-up period was 92.1 months (range, 2.8-310.3 months). At the time of analysis, 13 patients (15.1{\%}) died, and 36 patients (43.3{\%}) had local recurrence. The 7-year overall survival, freedom from neck lymph node recurrence, and local control (LC) rates for all patients were 83.5{\%}, 75.5{\%}, and 52.3{\%}, respectively. Patients with a tumor size ≤10 mm had a higher 7-year LC rate than those with a tumor size >10 mm (58.8{\%} vs 46.6{\%}, P = 0.054). Neck lymph node recurrence was observed in 17 patients (20{\%}) and significantly related to the tumor size. Late toxicity of an eyelid dysfunction of grade 3 was observed in 1 patient with T3 tumor. Radiotherapy for sebaceous carcinoma of the eyelid is a reasonable alternative to surgical resection for tumors <10 mm in size with few severe complications, while larger tumors should be treated with surgery if feasible.",
keywords = "eyelid, prognostic factor, radiotherapy, sebaceous carcinoma, toxicity",
author = "Yoshiaki Takagawa and Wakana Tamaki and Shigenobu Suzuki and Koji Inaba and Naoya Murakami and Kana Takahashi and Hiroshi Igaki and Yuko Nakayama and Naoyuki Shigematsu and Jun Itami",
year = "2019",
month = "10",
day = "23",
doi = "10.1093/jrr/rrz046",
language = "English",
volume = "60",
pages = "622--629",
journal = "Journal of Radiation Research",
issn = "0449-3060",
publisher = "Japan Radiation Research Society",
number = "5",

}

TY - JOUR

T1 - Radiotherapy for localized sebaceous carcinoma of the eyelid

T2 - a retrospective analysis of 83 patients

AU - Takagawa, Yoshiaki

AU - Tamaki, Wakana

AU - Suzuki, Shigenobu

AU - Inaba, Koji

AU - Murakami, Naoya

AU - Takahashi, Kana

AU - Igaki, Hiroshi

AU - Nakayama, Yuko

AU - Shigematsu, Naoyuki

AU - Itami, Jun

PY - 2019/10/23

Y1 - 2019/10/23

N2 - The current study retrospectively analyzed the results of radiotherapy for clinically localized sebaceous carcinoma of the eyelid.We reviewed records of 83 patients with histologically confirmed sebaceous carcinoma who were treated radiotherapeutically between 1983 and 2015. Sixty-five patients (78%) were initially treated with radiotherapy of curative intent, while the remaining 18 patients underwent postoperative radiotherapy due to tumor recurrence or positive surgical margins. Thirty-seven patients belonged to T1-2, while 46 belonged to T3-4. All 83 patients were treated with radiotherapy with a median radiation dose of 60 Gy. The median follow-up period was 92.1 months (range, 2.8-310.3 months). At the time of analysis, 13 patients (15.1%) died, and 36 patients (43.3%) had local recurrence. The 7-year overall survival, freedom from neck lymph node recurrence, and local control (LC) rates for all patients were 83.5%, 75.5%, and 52.3%, respectively. Patients with a tumor size ≤10 mm had a higher 7-year LC rate than those with a tumor size >10 mm (58.8% vs 46.6%, P = 0.054). Neck lymph node recurrence was observed in 17 patients (20%) and significantly related to the tumor size. Late toxicity of an eyelid dysfunction of grade 3 was observed in 1 patient with T3 tumor. Radiotherapy for sebaceous carcinoma of the eyelid is a reasonable alternative to surgical resection for tumors <10 mm in size with few severe complications, while larger tumors should be treated with surgery if feasible.

AB - The current study retrospectively analyzed the results of radiotherapy for clinically localized sebaceous carcinoma of the eyelid.We reviewed records of 83 patients with histologically confirmed sebaceous carcinoma who were treated radiotherapeutically between 1983 and 2015. Sixty-five patients (78%) were initially treated with radiotherapy of curative intent, while the remaining 18 patients underwent postoperative radiotherapy due to tumor recurrence or positive surgical margins. Thirty-seven patients belonged to T1-2, while 46 belonged to T3-4. All 83 patients were treated with radiotherapy with a median radiation dose of 60 Gy. The median follow-up period was 92.1 months (range, 2.8-310.3 months). At the time of analysis, 13 patients (15.1%) died, and 36 patients (43.3%) had local recurrence. The 7-year overall survival, freedom from neck lymph node recurrence, and local control (LC) rates for all patients were 83.5%, 75.5%, and 52.3%, respectively. Patients with a tumor size ≤10 mm had a higher 7-year LC rate than those with a tumor size >10 mm (58.8% vs 46.6%, P = 0.054). Neck lymph node recurrence was observed in 17 patients (20%) and significantly related to the tumor size. Late toxicity of an eyelid dysfunction of grade 3 was observed in 1 patient with T3 tumor. Radiotherapy for sebaceous carcinoma of the eyelid is a reasonable alternative to surgical resection for tumors <10 mm in size with few severe complications, while larger tumors should be treated with surgery if feasible.

KW - eyelid

KW - prognostic factor

KW - radiotherapy

KW - sebaceous carcinoma

KW - toxicity

UR - http://www.scopus.com/inward/record.url?scp=85074003497&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85074003497&partnerID=8YFLogxK

U2 - 10.1093/jrr/rrz046

DO - 10.1093/jrr/rrz046

M3 - Article

C2 - 31271440

AN - SCOPUS:85074003497

VL - 60

SP - 622

EP - 629

JO - Journal of Radiation Research

JF - Journal of Radiation Research

SN - 0449-3060

IS - 5

ER -